Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
PHASE2CompletedINTERVENTIONAL
Enrollment
77
Participants
Timeline
Start Date
May 8, 2014
Primary Completion Date
February 8, 2024
Study Completion Date
February 8, 2024
Conditions
CMV InfectionPersistent CMV Viremia
Interventions
BIOLOGICAL
CMVpp65 Specific T-cells
Trial Locations (1)
10065
Memorial Sloan Kettering Cancer Center, New York
All Listed Sponsors
lead
Memorial Sloan Kettering Cancer Center
OTHER
NCT02136797 - Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter